2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
102
Neoplasm Metastasis
26
Neoplasms
15
Brain Neoplasms
13
Prostatic Neoplasms
10
Endometrial Neoplasms
10
Carcinoma, Non-Small-Cell Lung
10
Ovarian Neoplasms
7
Glioblastoma
7
Glioma
6
Triple Negative Breast Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Head and Neck Neoplasms
5
Colorectal Neoplasms
5
Breast Diseases
5
Sarcoma
4
Recurrence
4
Pancreatic Neoplasms
4
Lymphoma, Non-Hodgkin
4
Sarcoma, Ewing
3
Osteosarcoma
3
Neoplasms by Site
3
Multiple Myeloma
3
Meningioma
3
Melanoma
3
Carcinoma, Renal Cell
3
Unilateral Breast Neoplasms
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Oligodendroglioma
2
Interventions
Fulvestrant
6
Letrozole
4
Capecitabine
4
exemestane
3
dalpiciclib
3
Trastuzumab
3
Docetaxel
3
Anastrozole
3
ribociclib
2
palbociclib
2
fluzoparib
2
apatinib
2
Irinotecan
2
Gemcitabine
2
tusamitamab ravtansine
1
trastuzumab deruxtecan
1
sacituzumab govitecan
1
pyrotinib
1
pegfilgrastim
1
patritumab deruxtecan
1
olaparib
1
nirogacestat
1
margetuximab
1
irinotecan sucrosofate
1
abemaciclib
1
Zoledronic Acid
1
Vinorelbine
1
Tamoxifen
1
Rogaratinib
1
Patient Reported Outcome Measures
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Cancer Metastatic
×
abemaciclib
×
Clear all
NCT04603183
2025-12-12
ABIGAIL
MedSIR
Phase 2
Completed
162 enrolled